Professor of Medicine, Dana-Farber Cancer Institute
Oncology
Dr. William C. Hahn, MD
|
|
Give Review
William Hahn is an expert in the field of Oncology. He attended Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. He over the years received 1 awards: "Elected Member". William C. Hahn is also published. He has 101 publications published. The lastest publication: "MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.' He is registered with Medicare and accepts Medicare payments.
Publications
- Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.
- MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in Cancer cells.
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.
- The androgen receptor cistrome is extensively reprogrammed in human Prostate tumorigenesis.
- SWI/SNF-mutant Cancers depend on catalytic and non-catalytic activity of EZH2.
- Oncogenic Signaling Adaptor Proteins.
- The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.
- A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer.
- DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
- An integrative analysis reveals functional targets of GATA6 transcriptional regulation in gastric Cancer.
- RNF43 is frequently mutated in colorectal and endometrial Cancers.
- An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma.
- Papillomavirus E7 Oncoproteins Share Functions with Polyomavirus Small T Antigens.
- BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers.
- Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation.
- Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S.
- Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients.
- PP2A-Mediated Regulation of Ras Signaling in G2 Is Essential for Stable Quiescence and Normal G1 Length.
- PRKACA mediates resistance to HER2-targeted therapy in breast Cancer cells and restores anti-apoptotic signaling.
- KRAS and YAP1 Converge to Regulate EMT and Tumor Survival.
- Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation.
- Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation.
- Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.
- Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits.
- ARID1B is a specific vulnerability in ARID1A-mutant Cancers.
- ZFHX4 Interacts with the NuRD Core Member CHD4 and Regulates the Glioblastoma Tumor-Initiating Cell State.
- In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian Cancer oncogene.
- Genomic insights into WNT/β-catenin signaling.
- TRAF2 is an NF-κB-activating oncogene in epithelial Cancers.
- Oncogenic mutations in cervical Cancer: Genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.
- Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1.
- ATARiS: Computational quantification of gene suppression phenotypes from multisample RNAi screens.
- Structure and Ubiquitination-Dependent Activation of TANK-Binding Kinase 1.
- IKK?-Mediated Tumorigenesis Requires K63-Linked Polyubiquitination by a cIAP1/cIAP2/TRAF2 E3Â Ubiquitin Ligase Complex.
- Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
- Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target.
- IúB Kinase {varepsilon} Phosphorylates TRAF2 To Promote Mammary Epithelial Cell Transformation.
- High throughput mass spectrometry-based mutation profiling of primary uveal melanoma.
- Targeted Tumor-Penetrating siRNA Nanocomplexes for Credentialing the Ovarian Cancer Oncogene ID4.
- Nek4 regulates entry into replicative senescence and the response to DNA-damage in human fibroblasts.
- MicroSCALE Screening Reveals Genetic Modifiers of Therapeutic Response in Melanoma.
- Emerging insights into the molecular and cellular basis of glioblastoma.
- High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.
- Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non-Small Cell Lung Cancers.
- Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion.
- Clinical implementation of comprehensive strategies to characterize Cancer genomes: opportunities and challenges.
- BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
- Systematic investigation of genetic vulnerabilities across Cancer cell lines reveals lineage-specific dependencies in ovarian Cancer.
- Telomerase and Retrotransposons: Reverse Transcriptases That Shaped Genomes Special Feature Sackler Colloquium: Maintenance of tumor initiating cells of defined geneti...
- A public genome-scale lentiviral expression library of human ORFs.
- Transformation-dependent Silencing of Tumor-selective Apoptosis-inducing TRAIL by DNA Hypermethylation is Antagonized by Decitabine.
- The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast Cancer cells in human tumors.
- Making sense of Cancer genomic data.
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling.
- RMRP Is a Non-Coding RNA Essential for Early Murine Development.
- High throughput interrogation of somatic mutations in high grade serous Cancer of the ovary.
- Identification of PP2A complexes and pathways involved in cell transformation.
- CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation.
- Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models.
- Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human Prostate tumorigenesis.
- Recurrent BRAF mutations in Langerhans cell histiocytosis.
- Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.
- CDK8 expression in 470 colorectal Cancers in relation to beta-catenin activation, other molecular alterations and patient survival.
- On or off target: mutations, models, and predictions.
- PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas.
- An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian Cancer cells.
- Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT.
- An oncogene-tumor suppressor cascade drives metastatic Prostate cancer by coordinately activating Ras and nuclear factor-kappaB.
- An oncogenic role for ETV1 in melanoma.
- CK1epsilon is required for breast Cancers dependent on beta-catenin activity.
- PTK6 regulates IGF-1-induced anchorage-independent survival.
- Therapeutic implications of GIPC1 silencing in Cancer.
- Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase.
- SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.
- Revving the Throttle on an oncogene: CDK8 takes the driver seat.
- Regulating TERT: location, location, location.
- Proteomic and genetic approaches identify Syk as an AML target.
- MYC activity mitigates response to rapamycin in Prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy.
- AKT-independent signaling downstream of oncogenic PIK3CA mutations in human Cancer.
- Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human Cancer cells.
- Phosphorylation of the tumor suppressor CYLD by the breast Cancer oncogene IKKepsilon promotes cell transformation.
- PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma.
- Fatty acid synthase: a metabolic enzyme and candidate oncogene in Prostate cancer.
- Bladder Cancer: modeling and translation.
- SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis.
- Profiling critical Cancer gene mutations in clinical tumor samples.
- Highly parallel identification of essential genes in Cancer cells.
- Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas Cancer.
- Suppression of hPOT1 in diploid human cells results in an hTERT-dependent alteration of telomere length dynamics.
- A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and Cancer progression.
- Unexpected pieces to the senescence puzzle.
- The current state of preclinical Prostate cancer animal models.
- Regulation of in situ to invasive breast carcinoma transition.
- Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development.
- Liprin alpha1 interacts with PP2A B56gamma.
- Oncogenic transformation and experimental models of human Cancer.
- The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon Cancer growth.
- BRAF activation initiates but does not maintain invasive Prostate adenocarcinoma.
- Malignant astrocytic glioma: genetics, biology, and paths to treatment.
- Structural basis of PP2A inhibition by small t antigen.
Schools
Harvard Medical School
Massachusetts General Hospital
Dana Farber Cancer Institute
Harvard University
Whitehead Institute
Conditions Treated
- Prostate Cancer
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Elected Member
Education
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Harvard Medical School
Hospital
-
Massachusetts General Hospital -
Dana-Farber Cancer Institute -
Brigham and Women's Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. Robert L. Schlossman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Glenn Dranoff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nikolaos Trikalinos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pasi A. Janne, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ian E. Krop, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven P. Treon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Irene M. Ghobrial, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert J. Soiffer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles Rosenbaum, MD
This Doctor is OpenDoctor Recommended.
|